



THE SECRETARY-GENERAL

24 July 2008

Dear Mr. White,

Over the last few years, representatives from the United Nations and leading pharmaceutical companies met to strengthen collective efforts to increase access to HIV diagnostics, treatment and care. In many countries, the AIDS epidemic is still outstripping our best efforts. There is an urgent need to continue working in close partnership to fortify the response to AIDS.

To build on the progress made to date, I am pleased to invite you to a round-table discussion, followed by dinner, on 9 October 2008 at United Nations Headquarters in New York. The round-table meeting has four specific objectives and these are to:


1. Strengthen the relationship between the United Nations and leading pharmaceutical companies at the highest levels,
2. Identify current gaps and opportunities for greater collaboration,
3. Send a clear message about our collective commitment to the AIDS response, and
4. Take stock of the individual, as well as collective, achievements since the last meeting held in July 2006 between the United Nations and top pharmaceutical companies working on AIDS.

Mr. Miles White  
Chairman of the Board  
and Chief Executive Officer  
Abbott Laboratories  
Illinois

It is my hope that you will be able to accept my invitation to participate in the round-table discussions. I have asked the Joint United Nations Programme on HIV/AIDS (UNAIDS) to work with participating companies to prepare the agenda and to provide specific details of the meeting. UNAIDS will also collaborate closely with the Global Fund to Fight AIDS, Tuberculosis and Malaria, the World Health Organization, the United Nations Children's Fund and the United Nations Development Fund to prepare for the meeting.

I look forward to receiving your reply and to welcoming you to the round table.

Yours sincerely,

A handwritten signature in black ink that reads "Ki Moon Ban". The signature is fluid and cursive, with a long horizontal stroke extending to the right from the end of the name.

BAN Ki-moon



THE SECRETARY-GENERAL

24 July 2008

Dear Ms. Veneman,

Over the last few years, representatives from the United Nations and leading pharmaceutical companies met to strengthen collective efforts to increase access to HIV diagnostics, treatment and care. In many countries, the AIDS epidemic is still outstripping our best efforts. There is an urgent need to continue working in close partnership to fortify the response to AIDS.

To build on the progress made to date, I am pleased to invite you to a round-table discussion, followed by dinner, on 9 October 2008 at United Nations Headquarters in New York. The round-table meeting has four specific objectives and these are to:


1. Strengthen the relationship between the United Nations and leading pharmaceutical companies at the highest levels,
2. Identify current gaps and opportunities for greater collaboration,
3. Send a clear message about our collective commitment to the AIDS response, and
4. Take stock of the individual, as well as collective, achievements since the last meeting held in July 2006 between the United Nations and top pharmaceutical companies working on AIDS.

Ms. Ann Veneman  
Executive Director  
UNICEF  
New York

It is my hope that you will be able to accept my invitation to participate in the round-table discussions. I have asked the Joint United Nations Programme on HIV/AIDS (UNAIDS) to work with participating companies to prepare the agenda and to provide specific details of the meeting. UNAIDS will also collaborate closely with the Global Fund to Fight AIDS, Tuberculosis and Malaria, the World Health Organization, the United Nations Children's Fund and the United Nations Development Fund to prepare for the meeting.

I look forward to receiving your reply and to welcoming you to the round table.

Yours sincerely,

A handwritten signature in black ink, reading "Ban Ki-moon". The signature is written in a cursive style with a long horizontal stroke at the end.

BAN Ki-moon

**List of Invitees to Secretary-General's meeting with the pharmaceutical  
and diagnostic companies**

**Mr. Miles White**, Chairman, Abbott Laboratories, **Illinois**

**Mr. Stavros Nicolaou**, Managing CEO, Aspen Pharmacare Holdings, **Johannesburg**

**Mr. P.V. Ramaprasad Reddy**, Chairman, Aurobindo Pharma Ltd, **Hyderabad**

**Mr. Gary Cohen**, VP, Becton Dickinson, **New Jersey**

**Mr. James M. Cornelius**, Chairman and CEO, Bristol-Myers Squibb, **New York**

**Mr. Amar Lulla**, Joint MD, Acting CEO, Cipla Ltd, **Mumbai**

**Mr. Gregg H. Alton**, SVP & General Council, Gilead, **California**

**Mr. Andrew Witty**, CEO, Glaxo Smith Kline UK Limited, **London**

**Mr. B. Parthasaradhi S. Reddy**, Chairman, Hetero Drugs Limited, **Hyderabad**

**Ms. Julie McHugh**, Company Group Chairman, Johnson and Johnson, **Pennsylvania**

**Mr. Robert J. Coury**, Chairman, Matrix Laboratories Ltd, **Secunderabad**

**Mr. Richard Clark**, Chairman, President and CEO, Merck, **New Jersey**

**Mr. Jeffrey Kindler**, CEO & Chairman of the Board, Pfizer, **New York**

**Mr. Malvinder Mohan Singh**, Managing Director, Ranbaxy Lab. Ltd, **Haryana**

**Mr. Severin Schwan**, CEO, F. Hoffmann-La Roche Ltd, **Geneva**

---

**Mr. Michael Kazatchkine**, Executive Director, The Global Fund to Fight AIDS, Tuberculosis and Malaria, **Geneva**

**Mr. Peter Piot**, Executive Director, Joint UN Programme on HIV/AIDS, **Geneva**

**Ms. Margaret Chan**, Director General, WHO, **Geneva**

**Ms. Ann Veneman**, Executive Director, UNICEF, **New York**

**Mr. Kemal Derviş**, Administrator, UNDP, **New York**

Drafter: Itai Madamombe  
Proofread by: Parfait Onanga  
Approved by: Parfait Onanga  
Authorized: \_\_\_\_\_  
Date: 24 July 2008